Newsroom

NEW YORK--(BUSINESS WIRE)--Samsung Ventures joins GridBeyond’s shareholder base as part of a €12M equity investment...

FRANKFURT, Alemania--(BUSINESS WIRE)--RS2, un proveedor global nivel 1 de infraestructura de procesamiento de pagos y soluciones de tecnología, anunció hoy el lanzamiento de Beyond by RS2, una nueva marca de pagos digitales diseñada para ayudar a que proveedores de pagos, plataformas y empresas fintech lancen rápidamente servicios de emisión de tarjetas y aceptación de pagos en Europa. Diseñada sobre la plataforma BankWORKS de RS2, comprobada a nivel mundial, Beyond by RS2 ofrece a las fintechs...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 16 March 2026 London, 16 March 2026 //‐ Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 16 March 2026 Number of Publi...

LONDON--(BUSINESS WIRE)--  ISIN Code. XS3184154394 Our Ref. MU3765 ISSUE NAME. City Of Goteborg Issue of SEK 650,000,000.00 Floating Rate Green Notes due September 2030 Series No GB45 Tranche 1 MTN INTEREST PERIOD. 18/03/2026 TO 18/06/2026 VALUE DATE. 18/06/2026 INTEREST RATE. 2.792 PCT NUM OF DAYS. 92 DAY BASIS. Actual/360 (A004) CURRENCY CODE. SEK TOTAL INTEREST AMT. SEK 4,637,822.22 POOL FACTOR. N/A...

GRENOBLE, France--(BUSINESS WIRE)--Teledyne e2v is pleased to announce the start of full production of its 16GB DDR4-X1 Flight Model (FM), expanding its portfolio of high-density, radiation-tolerant memory solutions for space applications. The new device is designed to support the growing processing and data storage requirements of AI-enabled satellites, large constellations, broadband Internet-from-Space, Direct-to-Device services, and optical inter-satellite communications. By combining high...

PARIS--(BUSINESS WIRE)--  In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from March 9 to March 13, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Amount of...

GENT, Belgien, und TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. und ihre 100-prozentige Tochtergesellschaft Fujirebio Holdings, Inc. (nachstehend „Fujirebio“) gaben heute bekannt, dass Fujirebio Europe N.V. die CE-Kennzeichnung für den Lumipulse G NfL-Bluttest gemäß der Verordnung (EU) 2017/746 über In-vitro-Diagnostika-Medizinprodukte (IVDR) erhalten hat. Der CLEIA-Test (chemolumineszierender Enzymimmunassay) ermöglicht die quantitative Messung der Neurofilament-Leichtkette (NfL) im Plasma...

GENT, Bélgica e TÓQUIO--(BUSINESS WIRE)--H.U. A Group Holdings Inc. e sua subsidiária integral, Fujirebio Holdings, Inc. (doravante “Fujirebio”), anunciaram hoje que a Fujirebio Europe N.V. obteve a certificação CE para o ensaio sanguíneo Lumipulse G NfL, em conformidade com o Regulamento (UE) 2017/746 sobre dispositivos médicos para diagnóstico in vitro (IVDR). Este teste CLEIA (ensaio imunoenzimático quimioluminescente) permite a medição quantitativa da cadeia leve de neurofilamento (NfL) no...

GAND, Belgique et TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale à 100 %, Fujirebio Holdings, Inc. (ci-après « Fujirebio »), ont annoncé aujourd’hui que Fujirebio Europe N.V. a obtenu le certificat CE pour le test sanguin Lumipulse G NfL conformément au règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro (IVDR). Ce test CLEIA (dosage immunoenzymatique par chimiluminescence) permet la mesure quantitative de la chaîne légère des neurofilaments (NfL) dan...

比利時，根特 & 東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其全資子公司Fujirebio Holdings, Inc.（以下簡稱「Fujirebio」）今天宣布Fujirebio Europe N.V.的Lumipulse G神經元絲 (NfL) 血液檢測儀通過歐盟2017/746有關體外診斷醫療器材 (IVDR) 的規範，取得CE認證。這種CLEIA（化學發光酶免疫測定）測試可以定量測量血漿和血清中的神經元絲。 「雖然我們的檢測清單上已經有許多強效的疾病特異性生物標記，但神經元絲的加入仍象徵一項重大突破：這是我們第一次取得CE標誌的血液檢測項目，能夠為臨床醫生提供跨大層面神經系統疾病的分析。」Fujirebio Europe N.V.執行長Christiaan De Wilde說，「我們很高興能將這項檢測獻給客戶，進一步擴大我們在LUMIPULSE G平台上的全自動神經系統疾病檢測解決方案組合。我們將繼續與世界各地的機構和臨床專家合作，致力提供更早期、更便利、更完整的神經系統疾病診斷工具。」 關於NfL 神經元...